Biology Reference
In-Depth Information
[139] Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn
MA, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-
specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad
Sci U S A 2003;100:2742-7.
[140] Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and per-
sistence of adoptively transferred autologous CD19-targeted T cells in patients with
relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118:4817-28.
[141] Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T
cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
[142] Mundhada S, Shaw J, Mori S, Savary CA, Mullen CA. Cellular tumor vaccines admin-
istered after T cell-depleted allogeneic bone marrow transplantation induce effective
anti-tumor immune responses. Leuk Lymphoma 2005;46:571-80.
[143] Ho VT, Vanneman M, Kim H, Sasada T, Kang YJ, Pasek M, et al. Biologic activity of ir-
radiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic
stem cell transplantation. Proc Natl Acad Sci U S A 2009;106:15825-30.
[144] Champlin R, Ho W, Gajewski J, Feig S, Burnison M, Holley G, et al. Selective depletion of
CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone
marrow transplantation. Blood 1990;76:418-23.
[145] Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B, et al. Randomized trial of
CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with
donor lymphocyte infusion. Biol Blood Marrow Transplant 2002;8:625-32.
[146] Hartwig UF, Robbers M, Wickenhauser C, Huber C. Murine acute graft-versus-host
disease can be prevented by depletion of alloreactive T lymphocytes using activation-
induced cell death. Blood 2002;99:3041-9.
[147] Fehse B, Frerk O, Goldmann M, Bulduk M, Zander AR. Efficient depletion of alloreactive
donor T lymphocytes based on expression of two activation-induced antigens (CD25
and CD69). Br J Haematol 2000;109:644-51.
[148] Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-hap-
loidentical bone marrow transplantation for hematologic malignancies using nonmy-
eloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol
Blood Marrow Transplant 2008;14:641-50.
[149] Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, et al. High-
dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host
disease. Blood 2010;115:3224-30.
[150] Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ, et al. Memory CD4+
T cells do not induce graft-versus-host disease. J Clin Invest 2003;112:101-8.
[151] Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ. Transfer of allogeneic CD62L− memory
T cells without graft-versus-host disease. Blood 2004;103:1534-41.
[152] Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte
infusions mediate superior graft-versus-leukemia effects in mixed compared to
fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood
2002;100:1903-9.
[153] Chakraverty R, Eom HS, Sachs J, Buchli J, Cotter P, Hsu R, et al. Host MHC class
II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-
versus-leukemia responses following delayed donor leukocyte infusions. Blood
2006;108:2106-13.
[154] Sykes M, Sheard MA, Sachs DH. Graft-versus-host-related immunosuppression is
induced in mixed chimeras by alloresponses against either host or donor lymphohe-
matopoietic cells. J Exp Med 1988;168:2391-6.
[155] Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG, et al. Lymphohematopoi-
etic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine
mixed chimeras established with a cyclophosphamide-based nonmyeloablative condi-
tioning regimen. Biol Blood Marrow Transplant 1999;5:133-43.
[156] Chakraverty R, Cote D, Buchli J, Cotter P, Hsu R, Zhao G, et al. An inflammatory check-
point regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J
Exp Med 2006;203:2021-31.
[157] Spitzer TR, McAfee SL, Dey BR, Colby C, Hope J, Grossberg H, et al. Nonmyeloablative
haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-
507)-based conditioning for refractory hematologic malignancies. Transplantation
2003;75:1748-51.
[158] Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, et al. Differential roles
of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin
Invest 1999;104:459-67.
[159] Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis
factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol
Blood Marrow Transplant 2003;9:292-303.
325
Search WWH ::
Custom Search